Navigation Links
Farnsworth 100 Hue Test

ProductsFarnsworth 100 Hue Test
Company Richmond Products, Inc.
Item Farnsworth 100 Hue Test
Features 
Description Farnsworth 100 Hue Test including MS-Excel scoring template on CD. The Richmond Products version of the Farnsworth 100 Hue Test comes boxed in clear acrylic containers which make scoring easy and reduces the potential for test disruption by holding the patients disc sequence intact. Farnsworth 100 Hue test from Richmond Products includes 93 color discs, four clear acrylic boxes, a tray, a durable laminated score template for copying, a supply of finger tip covers for the test subjects fingers (to maintain cleanliness and accuracy of the color discs), comprehensive instructions and a CD disk with a scoring template for use with MS-Excel. The scoring template calculates a numerical score and provides a graphical display or print of the patients score.
Info Richmond Products, Inc.Call Richmond Products, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-435-4770

Customer Service: 505-275-2406
Web site: http://www.richmondproducts.com

Related medicine products :

1. Magnetic Farnsworth D15 Kit
2. Farnsworths D15 Test
3. Farnsworth D-15 Test
4. Farnsworth Panel D15 test evaluation
5. Magnetic Farnsworth D15 kit
6. Farnsworth-Munsell 100 Hue Test
7. Farnsworth D15
8. Farnsworth 100 Hue
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig
... cross action. Round handle. Divides nucleus for p...ithout grooving. Nuclei of any hardness can be pre...er. Phaco of pre-chopped nuclear fragments is rapi...ving is diminished. Shortened ultra sound time and...
Karate chopper, spear shaped for ease of insertion into the nucleus.
Phaco chopper & iris retractor 2 mm cutting edge.
Medicine Products:
(Date:5/15/2008)..., 2008 -- The Society for Cardiovascular Angiogra...it will hold its 2009 Annual Scientific Sessions M...cused, collegial interventional cardiology meeting...ng time beginning in 2010. , The 2009 SCAI Annua...tional cardiology meeting of the spring for practi...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT)...ounced that, on May,12, 2008, it had received a NA...ompany,s requests for continued listing on The NAS...ed that the Company did not provide a,definitive p...mpliance with,the continued listing requirements o...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq... committed to,discovering, developing and commerci...orted unaudited financial results for the second f...orted a net loss attributable,to common stockholde...quarter ended March 31, 2008, as compared to a net...
(Date:5/15/2008)...wswire-USNewswire/ -- The American Public,Health A...r overwhelmingly,passing the 2008 farm bill and ur...egislation when it arrives on his desk., Along wi... broad,support among organizations representing th...utrition interests., "While this legislation is n...
Breaking Medicine News(10 mins):Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
... found anti-clotting drug called bivalirudin (Angi...rapy for patients with acute coronary syndromes su...s to be less risky for patients suffering from acu... the ‘Acute Catheterization and Urgent Interventio...
...e of bird flu had been discovered in a Farm in Sou...ing authorities to cull thousands more, South Kore...While speaking in a news conference, Kim Chang-sub...rantine department said: 'This case appears quite ...
...d safety officials have banned the sale of turbot ...ents in fish //at several of Beijing’s fish market...introduced by Cao Jilin from Europe in 1992. Due ...h are fed on medicinal supplements, which sometime...
...stitute for Health Information has grouped the fiv...real and Halifax into neighbourhoods, based on fiv...ants, people living alone and lone-parent families...d housing conditions and other social issues to kn...
Other Medicine News:Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Health Of Residents Is Affected by Various Factors 2
(Date:5/15/2008)...Showed Acceptable Tolerability Profile, ... WOODCLIFF LAKE, N.J., May 15 /- The ...sylate (E7389) demonstrated activity in a,heavily ...ed or metastatic,breast cancer, according to resul...study also suggests that eribulin mesylate has a m...
(Date:5/15/2008)...ated in Blacks, Hispanics/Latinos, People ...SIPPANY, N.J., May 15 /- Daiichi Sank...he American Society of,Hypertension,s Twenty- Thir...ans demonstrated that the powerful combination dru...afely and effectively helped,patients across sever...
(Date:5/15/2008)... /- Ergonex Pharma today,announced th...(FDA) has,granted orphan drug designation to Tergu...tension (PAH). Terguride is currently being evalua..., "The FDA,s grant of orphan drug designation to ...evelopment program by offering regulatory,clinica...
(Date:5/15/2008)...or an Antiplatelet Therapy that, Combined, with As...f Plavix/Iscover and Aspirin, According to a N..., May 15 /- Decision Resources, one o...for pharmaceutical and,healthcare issues, finds th...vement in patient compared to Sanofi-Aventis/Brist...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 1Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 4Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 1Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 2ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 1ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 2Vioxx Settlement Announced 6028 1
...gression Of Atherosclerosis,In People At Low-Risk*...6-AstraZeneca today announced that the,METEOR clin...,positive effect on atherosclerosis in people with...risk of coronary heart disease,(CHD). ,The study,... at,56th Scientific Sessions of the American Colle...
...wswire/ -- Once-daily,dosing with Otsuka,s investi...receptor antagonist, was associated with improveme... heart failure (ADHF),in hospitalized patients rec...t on their long-term survival versus placebo.(1) T...es of the,international landmark trial Efficacy of...
Other Medicine Technology:First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7